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Abstract: Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An 
emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient’s disease rather than 
employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to 
standard treatments between patients with disease of a similar pathological stage and grade, mutation- directed treatment may grow to be a viable 
tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that have 
been successfully antagonised by targeted therapeutics including their identification, the development of targeted compounds to combat them and 
the development of resistance to these therapies. This review will continue to examine these same mutations in the treatment and management of 
prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the potential or limitations 
for their use. 
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CANCER: A GENOMIC DISEASE 
 
Cancer is fundamentally a genomic disease. While cancer 
development can be triggered and aggravated by a number of 
factors, all human cancers are the result of changes in the 
DNA of a subject or in their epigenetic regulatory machinery. 
These aberrations can be inherent and hereditary [1, 2], 
precipitated by viral infections or other disease [3], a result of 
exposure to carcinogenic agents [4], or simply spontaneously 
arising in somatic cells. Each of these mechanisms has the 
potential to be exploited as molecular targets for therapeutic 
agents. This review will address the current ability to examine 
genomic information from individual patients’ cancers and how 
this can impact the unique landscape of prostate cancer at the 
clinical level. This review will continue by examining the rise 
and use of modern targeted therapeutic agents across cancer 
treatment and potential uses of these in the treatment of 
prostate cancer at various stages of the disease. 
 
EXPLORING THE HUMAN GENOME 
 
The first draft sequence of the human genome published 
in 2001 [5, 6], provided the foundation for clinical genome 
sequencing across a multitude of diseases. The initial public 
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effort, using revolutionary but limited technology, produced a 
3-gigabyte DNA sequence at a cost of $3 billion (US) in an 
undertaking that took thirteen years to complete. Today, the 
Next Generation Sequencing (NGS) technologies allow for a 
whole genome to be sequenced thirty fold for a little over 
$1,000, in a matter of days, providing feasibility for the 
application of genome sequencing in medical practice [7]. These 
technical advances also allow for high throughput targeted and 
exome sequencing, transcriptome sequencing and more recently 
methylome sequencing of bisulphite treated DNA, making it 
possible to examine both the genetic and epigenetic drivers of 
tumourigenesis. It has now become the detailed and 
integrated analysis of this data rather than the collection itself 
that limits the applications of genomic sequencing. Dr. Elaine 
Mardis of The Genome Institute, Washington, a leader in the 
field of genomics, commented that on analysing whole 
genome sequencing data “the required expertise to ‘solve’ each 
case included molecular and computational biologists, 
geneticists, pathologists and physicians with exquisite 
knowledge of the disease and of treatment modalities, research 
nurses, genetic counsellors, and IT and systems support 
specialists, among others” causing analysis to cost upwards of 
$100,000 [8]. However, ongoing advances in computational 
technologies and computational analyses are continuing to aid 
the interpretation of sequencing data and their routine clinical 
implementation. The efficient analysis of sequencing data is, 
of course, a necessary tool for any prospective mutation- 
directed treatment regimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TARGETED THERAPIES: VISION OR REALITY OR 
BOTH? 
 
Vision 
 
Mutation-directed treatment is an emerging medical field 
that aims to use an individual patient’s germline or tumour 
genetic profile to guide clinical decisions. Mutation-directed 
treatment aims to identify predictive and prognostic genetic 
markers which can be used to predict disease outcome and 
provide patient specific tailored treatment regimens [9]. In 
oncology in particular, current chemotherapy, radiation and 
surgical intervention strategies can result in significant short- 
term toxicities and long-term functional side effects. By 
accurately predicting response to specific targeted therapeutics 
it is possible to minimise the impact and associated health 
care costs of these side effects while simultaneously 
maximising the efficacy of treatment. 
 
 
Reality 
 
Producing targeted therapeutics has been an aspiration of 
both scientists and clinicians for many years. In 1902 the first 
link between genetic inheritance and predisposition to a 
disease was made by Sir Archibald Garrod in his work on 
alkaptonuria [10] and then in 1956 the first example for 
gene-dependent selective toxicity was discovered for the anti-
malarial drug primaquine [11]. However it is only relatively 
recently that non-hormonal targeted therapies have become a 
reality in the treatment of cancer. Malignancies including 
melanoma, breast, lung, and gastric cancers, and leukaemia are 
no longer treated solely by tissue type but are now able to be 
treated based on their molecular subtype, discoveries which 
will be covered in further detail in this review (Table 1). 
 
An additional challenge for mutation-directed treatment is 
the development of companion diagnostics to identify patients 
for treatment with targeted therapeutics. An excellent example 
of dual development of diagnostic and therapeutic is 
HercepTest and Herceptin (trastuzumab) which were approved 
for use only six months apart in 1998, the former to assess 
levels of HER2 expression and the latter treat HER2-positive 
breast cancer. Among other agencies, the US Food and Drug 
Administration (FDA) has recognised the importance for 
accurate diagnostics to accompany targeted therapeutics 
releasing guidelines in 2011 stating their intent to assess drugs 
and their companion diagnostics simultaneously [12]. Despite 
the progress in other tumour types, the question remains; is 
mutation-directed treatment a viable approach to the treatment 
of prostate cancer? 
 
 
Table 1. Clinical Trials of Targeted Therapeutics in Prostate Cancer. 
 
TARGET EGFR EGFR HER2 PI3K/Akt/mTOR 
Signalling Pathway 
ALK BCR-Abl BRACA1/2 
CANCERS 
APPROVED 
FOR 
TREATMENT 
 KRAS-dependent  mTOR EML4/ALK   
NSCLC, CRC, 
Breast Cancer, 
Leukaemia 
CRC Breast 
Cancer 
Her2-negative Breast 
Cancer, Renal Cell 
Carcinoma 
NSCLC Chronic 
Myeloid 
Leukaemia 
Breast Cancer 
THERAPEUTIC 
CLASS OF 
AGENT 
Erlotinib Cetuximab Trastuzumab Rapalogs Crizotinib Dasatinib Olaparib 
Tyrosine 
Kinase 
Inhibitor 
Chimeric IgG1 
monoclonal 
antibody 
Humanised 
IgG1 
monoclonal 
antibody 
Rapamycin derived 
mTORC1 inhibitors 
Alk targeting 
small 
molecule 
inhibitor 
Tyrosine 
Kinase 
Inhibitor 
PARP Inhibitor 
CaP TRIALS 
 
{n} denotes 
prostate cancer 
patients in multi- 
cancer trial 
Phase II 
Clinical Trial: 
n=29 
(chemotherapy 
a naïve) 
Phase II Clinical 
b Trial: n=38 
Phase II 
Clinical 
Trial: n=18 
c (CRPC) 
Pilot Study Trial 
d n=13 
No trial to 
date 
Phase III, 
randomised 
double-blind 
with docetaxel: 
n=1522 
chemotherapy 
naïve mCRPCe 
Phase II Clinical 
Trial: n=60{3}f 
CLINICAL 
RESPONSES 
2 patients had a 
partial 
response: 31% 
had clinical 
benefit: 9% 
progression 
free at 12 
months 
34% progression 
free survival rate 
at end point. 
Dependent on 
WT KRAS 
Poor 
efficacy 
Clinical response in 
17%: warrants 
further study 
 No comparable 
difference to 
docetaxel 
One patient with 
BRCA2 mutation 
– had >50% 
reduction in 
PSA levels, and 
decreases in 
bone metastases 
a[113], b[60], c[114], d[70], e[102], f[107]. 
 
 
THE PROMISE  OF MUTATION-DIRECTED 
TREATMENT IN PROSTATE CANCER 
 
The treatment of prostate cancer in the economically 
developed countries with long life expectancies is a significant 
medical challenge. Prostate cancer has the highest incidence 
rate, yet has on average a comparatively high 5 year survival 
rate of 92% [13]. Currently, determining the subset of patients 
with an aggressive form from those with a more indolent 
form of this disease remains problematic, as there are few 
biomarkers which have been identified to estimate the severity 
of prostate cancer progression. 
 
In routine clinical practice, patients are stratified according 
to the risk of disease progression based upon serum Prostate 
Specific Antigen (PSA), digital rectal examination, the 
Gleason Score of a diagnostic biopsy, and a variety of other 
factors such as age, race, family history, and comorbidities 
formulated through one of a number of nomagrams. Together, 
these inform clinicians and patients on which course of 
treatment to pursue – be it active surveillance, hormone 
therapy, radiation, chemotherapy, or a radical prostatectomy. 
These prognostic and diagnostic tools however, simply enable 
the clinician to estimate the patient’s disease severity at that 
point in time – they give no indication of if, how or when the 
cancer will progress. While low-risk prostate cancer patients 
have a high likelihood of disease-free survival regardless of 
treatment chosen [14], men presenting with high-risk disease 
are at greater risk for treatment failure by single treatment 
modalities [15]. This inability to accurately predict the outcome 
of a person’s disease is a prevalent cause of the high-rate of 
overtreatment currently seen in prostate cancer patients, and 
this can often result in significant morbidity as the side effects 
of currently available therapies can be severe. 
 
These factors alone would seem to point to prostate cancer 
treatment being an ideal field for mutation-directed treatment 
decision making and targeted therapeutics, however further 
unique aspects of the biology of prostate cancer, such as 
multifocality and heterogeneity, add both exciting avenues of 
enquiry and frustrating complications to this pursuit. 
 
Inter-tumour Heterogeneity in Prostate Cancer 
 
Prostate cancer patients have been observed to vary widely 
in their response to similar treatment regimens. Broad 
differences are elicited in all clinical outcomes following 
treatment including length of progression-free-survival, time 
to bio-chemical relapse, time to castrate resistance following 
androgen-deprivation therapy, time to mortality or even 
complete response [16, 17]. This degree of variation in response 
to current clinical practices is in part explained by a high 
degree of genetic differences between prostate cancers in 
different men [18]. In contrast to cancers such as leukaemia and 
non-small cell lung cancer (NSCLC) where the same driver 
mutation occurs in a high frequency of patients [19], prostate 
cancer in different men is often caused by genomic alterations 
(mutations, chromosomal rearrangements or epigenetic events) 
in different genes in different pathways, mutations that react 
differently to various treatments [20, 21]. It is this 
environment to which targeted 
therapeutics are well suited. By determining the drivers of an 
individual man’s cancer it is possible to predict to which 
treatments he will respond. However, it is into this space that 
the other facet of prostate cancer heterogeneity intrudes and 
it is an aspect which puts considerable pressure on the potential 
efficacy of targeted therapies. 
 
Intra-tumour Heterogeneity in Prostate Cancer 
 
Many cancers are thought to originate from a single 
progenitor cell which harbours multiple cancer causing 
mutations and from which all subsequent cancerous cells arise, 
linked by specific germline mutations [22]. However there is 
growing evidence that some forms of cancer can have multiple 
distinct origins in the same tumour [23, 24]. This polyclonal 
origin is believed to be the norm rather than the exception in 
prostate cancer with approximately 80% of prostate cancers 
being shown to have more than one genetically distinct sub-
population [25, 26]. Moreover, prostate cancer heterogeneity is 
amplified by significant genetic instability over the decade-
spanning natural history of the disease. In a mechanism termed 
chromoplexy, multiple double stranded DNA breaks accrue at 
specific sites. These events cause a high prevalence of 
genomic recombination events, which can have a profound 
impact on cancer progression [27]. Several studies have 
reported that the multi-focal development of prostate cancer 
can be due to both; the spontaneous origin of cancer at 
different sites in the prostate, and the spread of existing cancer 
which is then given its own characteristics by widespread 
genetic instability [28, 29]. Some studies have taken this idea 
even further to suggest that all focal sites in a prostate 
cancer are in fact of monoclonal origin but the impact of 
these studies has been hampered by small sample size [30]. 
When a prostate cancer spreads to other organs however, it 
has been shown that most metastatic sites within a patient 
originate from the same clone in the primary tumour [31]. 
These findings have also indicated that metastases that spread 
to bone or lymph nodes are more likely to have similar 
genetic characteristics [32]. 
 
Assessing Heterogeneity 
 
That within any particular example of prostate cancer 
several genetically distinct cancerous sites are present poses 
a particular challenge to mutation-directed treatment. There is 
the possibility that in identifying and actioning a targetable 
mutation a previously dormant clone that is unsusceptible to 
this treatment can be triggered to develop into a more 
aggressive disease by over-treatment [17]. As such it remains 
imperative to the use of targeted therapies to be able to 
accurately analyse multiple sites within the prostate for 
targetable mutations, an issue that is not yet resolved and yet 
an issue that is similarly faced when deriving the Gleason 
Score for prostate cancer, which remains one of prostate 
cancer’s primary prognostic tools. 
 
The changing landscape of cancer treatment has already 
afforded a number of ways to more efficiently treat specific 
molecular subsets of cancer across a number of cancer types. 
With this in mind this review will now address examples of 
successes in the development and use of targeted therapeutics 
and the possibilities or impracticalities of 
 
 
translating these drugs for use in improving prostate cancer 
diagnostics, prognostics and treatment. 
 
KEY GENETIC MUTATIONS THAT HAVE BEEN 
THERAPEUTICALLY TARGETED IN CANCER 
 
EGFR Family Kinases 
 
EGFR as a Therapeutic Target 
 
Mutations of the epidermal growth factor receptor (EGFR) 
are often referred to as tumourigenesis “driver mutations”. 
EGFR-activating mutations are frequently seen to be early 
events in cancer development and members of the EGFR 
(HER) family of tyrosine kinases regulate a number of 
cellular processes including; cell proliferation, apoptosis, neo-
vascularisation, and cell motility [33, 34]. 10 – 20% of patients 
with NSCLC at an advanced stage are positive for EGFR 
activating mutations and this has proven to be predictive in 
response to various receptor tyrosine kinase inhibitors (TKIs) 
in particular erlotinib and gefitinib [34]. In prostate cancer, one 
study found that 13% of primary prostate tumours had 
mutations in EGFR and 36% had EGFR over-expression. 
Prostate cancer patients with overexpression of EGFR are also 
known to have a significantly increased risk of biochemical 
relapse [35]. A different study, observing Chinese men, found 
10% of those profiled had an activating mutation in EGFR [36]. 
A thorough investigation of EGFR in 71 castrate-resistant 
prostate cancers showed there was EGFR expression in over 
75% of castrate-resistant cancers. This expression was not seen 
to be homogeneous within the cancer however, with most 
EGFR-expressing cancers showing 10-75% of tumour cells 
with EGFR expression [37]. In a trial of gefitinib by the 
National Cancer Institute of Canada-Clinical Trials Group in 
40 patients with hormone-refractory prostate cancer, no PSA 
or objective measurable response to treatment was recorded 
and quality-of-life decreased [38]. A suggested reason for this 
ineffectiveness of EGFR blockade therapies in prostate cancer 
is the subsequent autocrine activation of alternative receptors 
by the over-expression of the HER receptors and ligands. This 
cascade up-regulates HER2 and HER3 ultimately leading to 
increased HER3 phosphorylation which bypasses EGFR to 
activate the downstream PI3K/Akt survival pathway [39]. This 
potential mechanism is supported by pre-clinical data that has 
shown that erlotinib is effective in prostate cancer cells where 
EGFR levels were significantly higher than levels of the 
HER2 oncogene [40]. This leads to the possibility that 
combined inhibition of EGFR along with HER2 or HER3 may 
be effective in treating prostate cancer, a possibility supported 
in part by pre-clinical data finding that dual inhibition of 
EGFR and HER2 sensitised hormone-naive prostate cancer 
cells to androgen deprivation therapy [41]. 
 
HER2 as a Therapeutic Target 
 
A total of 15 – 30% of breast cancers have been shown to 
have amplification and/or overexpression of the HER2/neu 
oncogene and as such will respond to treatment with 
trastuzumab, a humanised IgG1 monoclonal antibody against 
the HER2/neu protein [42]. Resistance to trastuzumab has 
predictably been observed in pre-clinical experiments in which 
there are alterations downstream of HER2 in the 
HER2-signalling pathway, for example PI3K mutation, or down 
regulation of PTEN or p27 [43]. Additionally a number of 
studies have so far investigated targeting HER2 in the 
treatment of prostate cancer. The role of HER2 in prostate 
cancer, both in a treatment and prognostic sense remain unclear. 
A recent review of HER2/neu serum profiling has shown that 
the HER2 extracellular domain is detectable in the serum of 
prostate cancer patients and is mainly over-expressed in 
aggressive disease and castrate- resistant cancers [44] while a 
murine study of human xenografts showed that adding 
trastuzumab to standard chemotherapy could delay the onset of 
hormone- independence [45]. HER2 over-expression is seen 
in five out of eight prostate tumour metastases when compared 
to matched primary tumours and co-expression of EGFR and 
HER2 has been identified in four out of eight metastases in 
the same cohort [46], additionally a single agent clinical trial 
of lapatinib, a dual EGFR and HER2 inhibitor, found a response 
in a small subset of un-profiled patients with castrate-resistant 
disease [47]. Two phase II studies of the use of the HER2 
inhibitor pertuzumab in castrate-resistant prostate cancer 
failed to show any objective result of a PSA decline of 
greater than 50%. The results of these studies can perhaps be 
attributed to the prevalence of PTEN loss in prostate cancer or 
conversely to the fact that patients’ tumours in these studies 
were not profiled for HER2 or not able to be profiled for 
HER2 overexpression [48, 49], an oversight that is shared with 
many other studies of targeted therapies in prostate cancer. 
 
KRAS as an Indicator of Resistance 
 
A formative event in the development of several cancer 
types is the mutation of the KRAS oncogene, which instead 
of being a targetable event in itself can offer resistance to 
EGFR-targeting therapies. KRAS mutation is especially 
prevalent in colorectal cancer (CRC) occurring in 
approximately 40% of patients. During the past decade, the 
introduction of targeted therapies and novel chemotherapeutic 
agents has increased the median overall survival rate of 
patients with metastatic CRC [50, 51]. One drug, cetuximab, a 
chimeric IgG1 monoclonal antibody which binds with high 
specificity to EGFR and has been found to be effective in 
patients who have a wild type KRAS [52]. However mutant 
KRAS has been associated with resistance to TKI therapies, 
and a poor prognosis with cetuximab (Fig. 1) [53, 54]. 
Metastatic progression as well as disease relapse in prostate 
cancer has been linked to the activation of EGFR [55]. A recent 
phase II clinical trial involving thirty-eight patients with 
metastatic castration resistant prostate cancer that had 
previously failed docetaxel single-agent therapy, showed a 
34% incidence of progression-free survival at a 12 week time-
point after further treatment with docetaxel in combination 
cetuximab [56]. 
 
Another recent clinical study involving eighty-eight 
Chinese patients with prostate cancer has shown that EGFR 
mutations are more common than KRAS mutations in prostate 
cancer (with KRAS mutations occurring in ~2.5% of patients) 
[36]. This study also indicated that EGFR and KRAS mutations 
may be mutually exclusive in prostate cancer and therefore 
anti-EGFR treatment may be useful in 
 
 
 
 
Fig. (1). The action of cetuximab. In many cancers, including colorectal cancers (CRC), increased activity of the EGFR tyrosine kinase (TK) 
leads to over activation of the MAPK/ERK signalling cascade through the GTPase KRAS (A). Cetuximab, a chimeric IgG1 monoclonal antibody 
currently used in CRC, is able to bind to EGFR in place of its activating ligand and inhibit the activation of these oncogenic pathways (B). 
However in approximately 40% of CRC patients, an activating mutation in KRAS is able to bypass EGFR inhibition and activate the downstream 
cascades, making treatment with cetuximab ineffective (C). 
 
treating prostate cancer. WT KRAS status is now used as a 
predictive tool in determining treatment with anti- EGFR 
inhibitors in patients with CRC and this is currently being 
clinically tested in prostate cancer where the mutational status 
of each gene may prove to be as important as in CRC. 
 
PI3K/Akt/mTOR Pathway 
 
PI3K/Akt/mTOR as a Therapeutic Target 
 
The phosphatidylinositol 3-kinase/protein kinase- 
B/mammalian target of rapamycin (PI3K/Akt/mTOR) 
signalling pathway has been shown to be activated in cancer 
more frequently than any other pathway [57, 58]. The primary 
effect of PI3K pathway alterations is the downstream 
activation of mTOR in its two complexes, mTORC1 and 
mTORC2 to stimulate angiogenesis, protein synthesis, 
proliferation, survival and metastasis in many cancers 
including CRC and renal cell carcinoma [59, 60]. So far, despite 
its importance in cancer progression and metastasis, few 
PI3K-targeted agents have progressed through clinical 
trials due to lack of selectivity and toxic events [61]. Two 
therapeutic agents derived from rapamycin, everolimus and 
temsirolimus, inhibit the mTORC1 complex and have been 
approved by the FDA for use limited to four specific cancer 
sub-types. The recently completed BOLERO-3 study showed 
that addition of everolimus to trastuzumab and vinorelbine 
treatment resulted in a significant increase to progression-free 
survival in trastuzumab-resistant metastatic breast cancer 
patients [62]. Second-line everolimus treatment proved 
effective in metastatic renal cell carcinoma resulting in 19% 
of patients experiencing a partial response and 
62% of patients achieving a stable disease with median 
progression-free survival of 8 months [63]. 43% of primary 
prostate cancers and 65% of metastatic disease present with 
alterations to the PI3K pathway. The majority of these 
alterations in prostate cancers are deletions or mutations in 
PTEN (see below) but also common are deletions of FOXO1 
and FOXO3 and amplification of PIK3CA [64]. In addition 
pre-clinical studies have shown that exposure to long-term 
androgen deprivation therapy and docetaxel increased 
signalling in the PI3K pathway through phosphorylated Akt 
 
 
possibly contributing to castrate-resistance [65]. Despite 
promising preclinical results, the inhibition of mTORC1 with 
everolimus and temsirolimus in castrate-resistant prostate 
cancer has been unsuccessful with few responses and short time 
to clinical progression [66]. In addition pharmacodynamics has 
shown in men with intermediate- to high-risk localised prostate 
cancer that rapamycin and its derivatives are clearly inhibiting 
mTORC1 action but with no significant outcomes in 
pathological or clinical response [67, 68]. This inaction is 
possibly because of rapalogs’ inability to inhibit mTORC2 
which is known to activate Akt in prostate cancer cells [69]. 
Prostate cancer treatment may benefit more from treatment 
with a dual mTORC1/2 inhibitor but at this time these agents 
are only just beginning to enter early stage clinical trials. 
However recent pre- clinical studies on castrate-resistant 
prostate cancer cell lines trialling a novel dual PI3K and 
mTORC1/2 inhibitor NVP- BEZ235 has found promising 
results for future prostate cancer treatment. Cells treated with 
BEZ235 were found to have significant reduction in the 
levels of active Akt protein and were sensitised to docetaxel 
overcoming docetaxel resistance [70]. In a similar study with 
docetaxel-resistant castrate-resistant cell lines BEZ235 was 
also able to sensitise the cells to treatment with a TKI, showing 
a synergistic effect and another study showed that BEZ235 
improved the response of prostate cancer cells to 
radiotherapy [71, 72]. A further study of prostate cancer cell 
lines determined that the action of BEZ235 was independent of 
PTEN mutational status inducing cell death in both PTEN 
wild-type and PTEN null cells indicating that PTEN deficiency 
should not affect treatment outcomes [73]. The dual inhibition 
of mTORC1/2 appears at this early stage to be an exciting 
avenue for future prostate cancer treatment, however it will be 
necessary to determine the likelihood and prevalence of toxic 
side-effects that have outweighed the benefits of previously 
developed PI3K pathway inhibitors [61]. 
 
PTEN as a Prognostic Marker 
 
Loss of function of the PTEN tumour suppressor through 
a variety of mechanisms has been observed in many types of 
human tumour; including brain, kidney, endometrium, breast, 
and prostate at a frequency that can rival p53 silencing [74]. In 
prostate alone, decreases in PTEN protein levels are observed 
in 70% of surgically removed cancers [75]. The prognosis of 
prostate cancer patients with PTEN loss is statistically poorer, 
with loss of expression being correlated with advanced stage, 
high grade cancer [76], promotion of microvessel growth [77], 
a shorter time to metastasis [78], and an increased incidence 
of biochemical and local recurrence [79]. Furthermore, studies 
have discovered that combined deletion of PTEN and p53 
leads to the development of much more aggressive tumours 
when compared to cancers with deletions in one gene [80]. 
Notably, PTEN expression for prognostic purposes in prostate 
cancer must be profiled at the protein level as it has been 
demonstrated that PTEN can be antagonised at the protein level 
without changes to DNA or RNA expression [81]. However 
with the correlations between PTEN expression and severity of 
prostate cancer, an early-stage PTEN screen would be a 
valuable resource in informing treatment decisions. 
Targetable Fusion Mutations in Cancer 
 
ALK as a Therapeutic Target 
 
The EML4-ALK fusion oncogene is a mutant kinase that 
has been shown to exhibit strong oncogenic activity but can 
be effectively suppressed by ALK-targeting small molecule 
inhibitors [82]. EML4-ALK appears in 3-6% of NSCLC patients 
or 10-20% when the cohort is restricted to younger, non-
smoking patients but a phase III trial of the ALK- inhibitor 
crizotinib in combination with platinum chemotherapy in this 
subset of patients found a 51% reduction in the risk of disease 
progression and a more than three-fold increase in the rate of 
response to radiotherapy [83]. Resistance to crizotinib in 
cancer can be conferred by two secondary mutations in the 
EML4-ALK kinase domain, [84]. Both mutations act by 
reducing the binding affinity of crizotinib for ALK and 
consequently another ALK inhibitor may not be affected in 
the same manner [85, 86]. Different ALK fusion mutations 
have also been reported in a growing group of other cancers 
including lymphoma, renal and soft tissue but to date NSCLC 
is the only malignancy to benefit from ALK-targeting. ALK 
activation has recently been identified in different metastatic 
sites in five different patients with castration-resistant prostate 
cancer using phosphoproteomic profiling [87] however no 
trials of ALK- inhibitors have been conducted in prostate 
cancer treatment at the time of writing, leaving this a possible 
avenue of further enquiry. 
 
BCR-ABL as a Therapeutic Target 
 
The BCR-ABL fusion gene produces a continuously active 
tyrosine kinase lacking the regulatory elements typically found 
in tyrosine kinases [88-90]. The constitutive kinase activity of 
BCR-ABL is well documented in chronic myeloid leukaemia 
(CML) [91] and can be treated by imatinib, an effective BCR-
ABL inhibitor [92, 93]. Imatinib was demonstrated in clinical 
trials to increase the survival of CML patients past 8 years to 
95.2%, similar to the rate of survival in the general population, 
essentially curing the disease. Less than 1% of patients in the 
study died of leukaemia progression [94]. Regardless of 
imatinib’s success in treating CML, a number of resistance 
mechanisms have developed including; methylation of SOCS3 
which activates STAT3 to increase cell proliferation [95], the 
release of reactive oxygen species from the mitochondria 
elevating levels of 8-oxo-guanine [96], increased expression of 
BCR- ABL, the expression of multidrug-resistant P-
glycoprotein (MDR-1), or mutation of the BCR-ABL kinase 
domain [97]. Additionally the effects of imatinib have had 
limited translational capabilities in different cancers. The 
effects of imatinib have been negligible in prostate cancer 
across multiple trials testing imatinib against PSA-progression 
following local therapy, biochemical recurrences, and castrate 
resistant disease [98-100]. An imatinib second- generation 
drug, dasatinib, showed promising effects in phase II clinical 
trials in hormone-refractory prostate cancer with observations 
that dasatinib has a positive response in bony metastases 
[101]. Although, further phase III trials have shown no 
survival benefit when compared to docetaxel in metastatic 
castrate-resistant disease [102]. However, there have been few 
trials which have directly profiled BCR-ABL 
 in early-stage or castrate-resistant prostate cancer and as such, 
success with BCR-ABL inhibitors was always unlikely. Future 
trials of imatinib or its derivatives must first establish the 
presence of BCR-ABL or a similar target in prostate cancers 
before attempting treatment. 
 
BRCA-1 and BRCA-2 as a Therapeutic Target 
 
A significant breakthrough in mutation-directed treatment 
was the identification of the correlation of BRCA-1 and 
BRCA-2 mutations to the risk of breast cancer in women. 
There is a 45-65% occurrence of women carrying a mutation 
in either of these genes developing breast cancer by the age 
of seventy [1]. This increased cancer risk is not only restricted 
to breast cancer, as these mutations also increase the risk of 
ovarian, colon and prostate cancers [103]. In particular men 
with a BRCA-1/2 mutation have a 1.6-8.6 fold greater risk of 
developing prostate cancer [104]. Specifically for men who 
possess a BRCA-1 mutation, studies have shown carriers 
develop prostate cancer at a younger age and with a more 
aggressive form of disease, distant metastases, and an 
increased mortality rate as compared to non-carriers [2, 105]. 
Furthermore a germline mutation in BRCA-2 has been found 
to be present in approximately two per cent of men who 
present with prostate cancer at an early age [106]. Although 
this mutation could be used as a prognostic it should be used in 
conjunction with additional genetic screening since it only 
affects around 3% of prostate cancers and may be of more 
use in young men to inform them of their need for regular 
screening later in life. BRCA deficient cells have become a 
target of mutation-directed treatment as they have been found 
to exhibit synthetic lethality, a situation in which disruption of 
one of two alternate pathways promotes survival while the 
subsequent inactivation of the second pathway with a 
therapeutic drug will cause cell death. In this case, BRCA 
deficient cells lack the homologous- recombination DNA 
repair mechanism but retain the mechanisms for the alternative 
base-excision DNA repair allowing tumour cells to escape the 
apoptotic cell death normally triggered by DNA damage. A 
recent phase I clinical trial of 60 patients, 22 of which had a 
germline BRCA-1 or BCRA-2 mutation has shown that BRCA 
mutation carriers with solid tumours, including prostate, had 
a higher response rate to olaparib, a Poly ADP-ribose 
Polymerase (PARP) inhibitor [107]. All patients in this trial 
had failed standard therapies to their disease, and five per 
cent of those recruited had prostate cancer. One patient with 
castration- resistant prostate cancer was a BRCA-2 mutation 
carrier, and following olaparib treatment, had more than a 
50% reduction in PSA level and resolution of bone 
metastases. In total, 63% of the patients in this trial who 
reached the end stage of treatment had a clinical benefit from 
this PARP-inhibitor. Olaparib enables selective cytotoxicity by 
preventing base- excision repair occurring in BRCA deficient 
cells, but normal cells that have functional homologous 
recombination pathways are not affected. Despite the benefits 
of olaparib as a cancer therapy, resistance to this therapy can 
occur. Therapy resistance arises through an intragenic in-
frame deletion that removes the initial BRCA-2 mutation and 
restores BRCA-2 protein function in tumour cells [108]. This 
deletion that restores BRCA-2 function is facilitated by error-
prone DNA repair, originally caused by the loss of 
BRCA-2 [109]. A recent study which sequenced samples from 
45 patients with either localised prostate cancer, metastatic 
hormone naïve prostate cancer, or metastatic castration resistant 
prostate cancer found that a BRCA-2 gene deletion occurred 
frequently in castrate resistant prostate cancer (20%) [110]. 
Therefore PARP inhibitors could possibly be an avenue of 
treatment in castrate-resistant disease, however further studies 
are required to determine their effectiveness in castrate resistant 
prostate cancer patients. Additionally, pre-clinical data in a 
recent study has found that olaparib may be effective in treating 
prostate cancer with a TMPRSS:ERG mutation [111]. 
 
p53 as a Prognostic Marker 
 
The most common genetic cancer mutation, found in more 
than 50% of human cancers, is a TP53 gene mutation [112]. 
The p53 protein is responsible for suspending the cell cycle 
after DNA damage recognition, activating of DNA repair 
proteins, and initiating apoptosis. In 25-40% of prostate cancer 
patients, there is a deletion in the TP53 locus, and a point 
mutation in 5-40% of prostate cancer samples [110]. The 
central dogma for the past few years has been that a TP53 
mutation drove late stage prostate cancer progression [66]. In 
a recent study using genetically engineered mouse models, it 
was found that a TP53 mutation might act as an initiating 
factor in prostate cancer progression [67]. A further trial of 
over 7000 prostate cancers has shown that different types of 
p53 loss have a variable impact on prognosis. Prostate cancers 
with a truncation or deletion of one allele of TP53 showed a 
poorer outcome than patients with normal p53 function and the 
data also showed that these patients presented with a less 
aggressive disease than those with homozygous p53 
inactivation. 
 
Interestingly though, patients found to have one mutated 
allele of TP53 were found to have a far worse prognosis than 
those with one inactive allele [68]. In a very recent study, an 
analysis of mutations specifically associated with metastasis 
in prostate cancer has revealed an enrichment of DNA repair 
and TP53 missense mutations, and additional sequencing of 
metastases from an independent cohort (n=19) has demonstrated 
that the late acquisition of TP53 mutations in primary tumour 
subclones is linked with expansion of subclones with metastatic 
potential [31]. These findings suggest that mutated forms of 
p53 are dominant-negative or even oncogenic, as has been 
shown in breast and lung cancer, and that profiling the variety 
of p53 mutations found in prostate cancer may have 
prognostic benefit. 
 
CONCLUSION 
 
Currently, it can be considered that there are two approaches 
to mutation directed treatment. The first, which can be 
described as screen based, aims to use genetic sequencing 
technology to screen the entirety of a person’s genome and 
seeks to identify the individual driving mutations of the cancer 
to which there may or may not be a therapeutic agent. The 
second, which can be described as drug-based, designs a screen 
to search a person’s cancer genome for mutations for which 
there exist therapeutic agents. The drug-based approach 
enables the restriction of a search to relevant mutations and 
enables time and resources 
 
 
to be saved whilst efficiently determining whether or not a 
particular patient can be aided by treatment with one of the 
currently available targeted therapeutics, whilst the screen- 
based approach takes more time and resources whilst holding 
the possibility that the driving mutation may as yet be 
untreatable. Limiting the search in favour of drug-based 
medicine, however, proposes the chance that a new driving 
mutation could be overlooked. One such screen-based program 
is already underway. The Michigan Oncology Sequencing 
Project (MI-ONCOSEQ) aims to bring individualised treatment 
to patients with advanced cancer by using whole genome 
sequencing to search a tumour for targetable mutations. The 
project began in 2011 as a pilot to discover the feasibility of 
using genomic sequencing in routine clinical care and is still 
continuing today [113]. Results of this project have so far 
allowed the MI- ONCOSEQ group to also characterise a 
number of interesting biological interactions in a number of 
cancers that offer potentially novel targets for targeted 
therapeutics [114-116]. 
 
Despite the weaknesses of both approaches, they both pose 
immense benefits in terms of cancer treatment. Therapeutics 
would be tailored to a patient, and even if resistance were to 
arise, it is possible that the patient could be re-screened and 
the appropriate therapeutics could be administered to overcome 
this. However there are a number of pitfalls to utilizing 
targeted therapies in the treatment of prostate cancer, the 
foremost of which is often the design of clinical trials. Many 
clinical trials that have been mentioned in this review draw 
conclusions from trials of mutation- specific drugs that are 
hampered by the absence of testing patients for mutational 
status [48, 49, 98-100]. Designing a screen based clinical trial 
would enable a transition into targeted therapies in the treatment 
of prostate cancer, and could also potentially lead to an 
indication of the key drivers in prostate cancer. Over the years, 
this road of mutation targeted therapy has become more 
accessible due to the decrease in genome sequencing cost and 
time, and an increase in the data output. Combined with 
bioinformatics, key mutations in an individual’s cancer can be 
readily identified and known therapeutics can be administered. 
As global rates of prostate cancer continue to climb and the 
issue of over-treatment of the disease continues to exist, a 
tailored approach to an individual’s treatment promises to be 
a boon to both clinicians and prostate cancer patients 
worldwide. 
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